Literature DB >> 10390360

Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line.

V Lohmann1, F Körner, J Koch, U Herian, L Theilmann, R Bartenschlager.   

Abstract

An estimated 170 million persons worldwide are infected with hepatitis C virus (HCV), a major cause of chronic liver disease. Despite increasing knowledge of genome structure and individual viral proteins, studies on virus replication and pathogenesis have been hampered by the lack of reliable and efficient cell culture systems. A full-length consensus genome was cloned from viral RNA isolated from an infected human liver and used to construct subgenomic selectable replicons. Upon transfection into a human hepatoma cell line, these RNAs were found to replicate to high levels, permitting metabolic radiolabeling of viral RNA and proteins. This work defines the structure of HCV replicons functional in cell culture and provides the basis for a long-sought cellular system that should allow detailed molecular studies of HCV and the development of antiviral drugs.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10390360     DOI: 10.1126/science.285.5424.110

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  1007 in total

Review 1.  Perspectives for the treatment of infections with Flaviviridae.

Authors:  P Leyssen; E De Clercq; J Neyts
Journal:  Clin Microbiol Rev       Date:  2000-01       Impact factor: 26.132

2.  Host cell factor requirement for hepatitis C virus enzyme maturation.

Authors:  L Waxman; M Whitney; B A Pollok; L C Kuo; P L Darke
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-13       Impact factor: 11.205

3.  Molecular biology of liver disorders:the hepatitis C virus and molecular targets for drug development.

Authors:  Howard J Worman; Feng Lin
Journal:  World J Gastroenterol       Date:  2000-08       Impact factor: 5.742

4.  Identification of a hepatic factor capable of supporting hepatitis C virus replication in a nonpermissive cell line.

Authors:  C T Yeh; H Y Lai; T C Chen; C M Chu; Y F Liaw
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

5.  Poly(C)-binding protein 2 interacts with sequences required for viral replication in the hepatitis C virus (HCV) 5' untranslated region and directs HCV RNA replication through circularizing the viral genome.

Authors:  Linya Wang; King-Song Jeng; Michael M C Lai
Journal:  J Virol       Date:  2011-06-01       Impact factor: 5.103

6.  In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor.

Authors:  Tse-I Lin; Oliver Lenz; Gregory Fanning; Thierry Verbinnen; Frédéric Delouvroy; Annick Scholliers; Katrien Vermeiren; Asa Rosenquist; Michael Edlund; Bertil Samuelsson; Lotta Vrang; Herman de Kock; Piet Wigerinck; Pierre Raboisson; Kenneth Simmen
Journal:  Antimicrob Agents Chemother       Date:  2009-01-26       Impact factor: 5.191

7.  Cytopathic and noncytopathic interferon responses in cells expressing hepatitis C virus subgenomic replicons.

Authors:  Ju-Tao Guo; Qing Zhu; Christoph Seeger
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

8.  Viral RNA mutations are region specific and increased by ribavirin in a full-length hepatitis C virus replication system.

Authors:  Ana Maria Contreras; Yoichi Hiasa; Wenping He; Adam Terella; Emmett V Schmidt; Raymond T Chung
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

9.  Identification of novel small-molecule inhibitors of West Nile virus infection.

Authors:  Amine O Noueiry; Paul D Olivo; Urszula Slomczynska; Yi Zhou; Ben Buscher; Brian Geiss; Michael Engle; Robert M Roth; Kyung Min Chung; Melanie Samuel; Michael S Diamond
Journal:  J Virol       Date:  2007-08-22       Impact factor: 5.103

10.  Responses of nontransformed human hepatocytes to conditional expression of full-length hepatitis C virus open reading frame.

Authors:  Weiliang Tang; Catherine A Lázaro; Jean S Campbell; W Tony Parks; Michael G Katze; Nelson Fausto
Journal:  Am J Pathol       Date:  2007-11-08       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.